Organization
Cambridge, United Kingdom
5 abstracts
Abstract
Predicting response to immune checkpoint blockade in recurrent/metastatic head and neck squamous cell carcinoma using personalized circulating tumor DNA.Org: Cambridge, United Kingdom,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).Org: Gustave Roussy and Paris Saclay University, Villejuif, France, Faculty of Medicine, Cairo University, Villejuif / Kremlin-Bicêtre, France, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).Org: University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom, Cardiff University School of Medicine, Cardiff, United Kingdom, The Christie and Salford Royal Hospital NHS Foundation Trusts,
Abstract
AZITHROMYCIN (AZ) IN REACTIVE ARTHRITIS (REA): A EULAR DOUBLE-BLIND STUDY COMPARING SHORT VERSUS LONG-TERM ANTIBIOTICSOrg: Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, Zurich, Switzerland, Paris, France, Vilnius, Lithuania, Amsterdam, Netherlands,